Homozygous familial hypercholesterolaemia

Active Ingredient: Atorvastatin

Indication for Atorvastatin

Population group: only children (1 year - 12 years old) , adolescents (12 years - 18 years old) , adults (18 years old or older)

Therapeutic intent: Curative procedure

For this indication, competent medicine agencies globally authorize below treatments:

10 mg once daily for at least 4 weeks and thereafter 80 mg once daily

For:

Dosage regimens

Oral, 10 milligrams atorvastatin, once daily, over the duration of 4 weeks. Afterwards, oral, between 10 milligrams atorvastatin and 80 milligrams atorvastatin, once daily. The maximum allowed total dose is 80 milligrams atorvastatin daily.

Detailed description

Only limited data are available. The dose of atorvastatin in patients with homozygous familial hypercholesterolemia is 10 to 80 mg daily. Atorvastatin should be used as an adjunct to other lipid-lowering treatments (e.g. LDL apheresis) in these patients or if such treatments are unavailable.

The patient should be placed on a standard cholesterol-lowering diet before receiving atorvastatin and should continue on this diet during treatment with atorvastatin.

The dose should be individualised according to baseline LDL-C levels, the goal of therapy, and patient response.

The usual starting dose is 10 mg once a day. Adjustment of dose should be made at intervals of 4 weeks or more. The maximum dose is 80 mg once a day.

Dosage considerations

Each daily dose of atorvastatin is given all at once and may be given at any time of day with or without food.

Active ingredient

Atorvastatin
Atorvastatin is a selective, competitive inhibitor of HMG-CoA reductase. Atorvastatin lowers plasma cholesterol and lipoprotein serum concentrations by inhibiting HMG-CoA reductase and subsequently cholesterol biosynthesis in the liver and increases the number of hepatic LDL receptors on the cell surface for enhanced uptake and catabolism of LDL. Read more about Atorvastatin

Related medicines

Summary of Product Characteristics (SPC) 2023: LIPITOR Film-coated tablet

Structured Product Labeling (SPL/PLR) 2022: LIPITOR Film-coated tablet

Develop a tailored medication plan for your case, considering factors such as age, gender, and health history

Ask the Reasoner

Liability Disclaimer : RxReasoner has utilized reasonable care in providing content and services that are accurate, complete and up to date. However, RxReasoner does not accept any responsibility or liability about it. The content and services of RxReasoner are for informational purposes only and they are not intended to be a substitute for the knowledge, expertise, skill, and judgment of physicians, pharmacists, nurses, or other healthcare professionals involved in patient care. RxReasoner offers no medical advice. Users are responsible for the use of the provided content. A shown indication or treatment should not be construed to indicate that the medication is safe, appropriate, or effective in any given patient or under any particular circumstances. The absence of an indication or treatment should not roule out the existence of other appropriate medications. Always seek the advice of a physician or other qualified health provider with any questions you may have regarding a medical condition or medicament. RxReasoner is not liable for any damages allegedly sustained arising out of the use of its content and services.